Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 356

1.

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.

Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA.

Leuk Lymphoma. 2008 Sep;49(9):1745-51. doi: 10.1080/10428190802226425.

PMID:
18798109
2.

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.

Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y.

Eur J Haematol. 2008 Dec;81(6):448-53. doi: 10.1111/j.1600-0609.2008.01129.x. Epub 2008 Aug 6.

PMID:
18691256
3.

Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.

Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN.

Am J Hematol. 2009 Feb;84(2):93-7. doi: 10.1002/ajh.21337.

4.
5.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM.

Blood. 2007 Mar 1;109(5):1857-61. Epub 2006 Nov 14.

6.

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.

Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN.

Bone Marrow Transplant. 2004 Feb;33(3):291-8.

PMID:
14676784
7.

Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.

Markovic O, Popovic L, Marisavljevic D, Jovanovic D, Filipovic B, Stanisavljevic D, Matovina-Brko G, Hajder J, Matkovic T, Živkovic R, Stanisavljevic N, Todorović M, Petrovic D, Mihaljevic B.

Eur J Intern Med. 2014 Mar;25(3):296-302. doi: 10.1016/j.ejim.2014.01.019. Epub 2014 Feb 22.

PMID:
24565533
8.

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB.

Ann Hematol. 2013 Nov;92(11):1513-20. doi: 10.1007/s00277-013-1807-0. Epub 2013 Jun 18.

PMID:
23775580
9.

Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.

Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G.

Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):131-41. doi: 10.1007/s00005-010-0066-1. Epub 2010 Feb 27.

PMID:
20191326
10.

CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.

Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M.

Am J Hematol. 2013 Apr;88(4):273-6. doi: 10.1002/ajh.23398. Epub 2013 Mar 5.

12.

Prognosis of localized diffuse large B-cell lymphoma in younger patients.

Møller MB, Christensen BE, Pedersen NT.

Cancer. 2003 Aug 1;98(3):516-21.

13.

PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma.

Schaffel R, Morais JC, Biasoli I, Lima J, Scheliga A, Romano S, Milito C, Spector N.

Mod Pathol. 2007 Mar;20(3):326-30. Epub 2007 Jan 19.

14.

Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.

Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST.

Ann Hematol. 2009 May;88(5):417-24. doi: 10.1007/s00277-008-0604-7. Epub 2008 Sep 7.

PMID:
18777110
15.

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS.

Blood. 2002 Feb 15;99(4):1136-43.

16.

Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.

Li YL, Pan YY, Jiao Y, Ning J, Fan YG, Zhai ZM.

Ann Hematol. 2014 Apr;93(4):617-26. doi: 10.1007/s00277-013-1916-9. Epub 2013 Oct 19.

PMID:
24141331
17.

New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.

Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN.

Biol Blood Marrow Transplant. 2010 Mar;16(3):376-83. doi: 10.1016/j.bbmt.2009.10.029. Epub 2009 Oct 31.

18.

Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.

Kim H, Sohn HJ, Kim SE, Kang HJ, Park S, Kim S, Kim WK, Lee JS, Suh C.

Bone Marrow Transplant. 2004 Jul;34(1):43-9.

PMID:
15107814
19.

[Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].

Wen J, Zhou J, Liu Z, Liu T, Xu C.

Zhonghua Xue Ye Xue Za Zhi. 2014 Apr;35(4):318-24. doi: 10.3760/cma.j.issn.0253-2727.2014.04.015. Chinese.

PMID:
24759020
20.

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.

Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Markovic SN.

Bone Marrow Transplant. 2006 May;37(9):865-71.

PMID:
16532015

Supplemental Content

Support Center